NCT02429271已完成3 期
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
Hellenic Cardiovascular Research Society1 个研究点 分布在 1 个国家目标入组 336 人开始时间: 2015年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 336
- 试验地点
- 1
- 主要终点
- The difference in Post PCI Corrected TIMI Frame Count (CTFC) between the ticagrelor and clopidogrel treatment arms.
研究概览
简要总结
This is a prospective randomized study, which investigates the coronary microvascular function as assessed by coronary angiography after administration of ticagrelor compared with clopidogrel in patients with myocardial infarction and ST segment elevation after thrombolysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of informed consent prior to any study specific procedures.
- •Male and female subjects, 18-75 years of age (both inclusive).
- •STEMI eligible for thrombolysis
- •Inability to perform primary PCI, because of transport time in centers carrying out primary PCI lasting more than two hours
- •Ability of transportation in 3-24 hours after thrombolysis in order to perform coronary angiography and PCI. This period may be extended for reasons of extreme importance up to 72 hours at the latest.
排除标准
- •Inability to give informed consent.
- •Pre-treatment with any inhibitor of the purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) within the 7-day period prior to randomization.
- •Cardiogenic shock - according to Killip classification - class
- •Suspicion or evidence of mechanical complication, including mitral valve dysfunction, ventricular septal rupture, and rupture of the left ventricle.
- •Current use of warfarin or other anticoagulant drug.
- •Known multivessel coronary artery disease not suitable for revascularization.
- •Any contraindication to thrombolytic therapy -Central nervous system damage or neoplasms or atrioventricular malformation -Recent major trauma/surgery/head injury (within the preceding 3 weeks) -Gastrointestinal bleeding within the past month -Known bleeding disorder (excluding menses) -Aortic dissection -Non-compressible punctures in the past 24 hours (e.g. liver biopsy, lumbar puncture).
- •Other bleeding diathesis, or considered by Investigator to be at high risk for bleeding.
- •Any kind of stroke in the past year or haemorrhagic stroke ever.
- •Severe uncontrolled hypertension (>180/110 mmHg) prior to randomisation.
- •Prolonged or traumatic cardiopulmonary resuscitation (> 10 minutes) in the last 2 weeks.
- •Known thrombocytopenia defined as platelet count of <100,000/mm
- •Known anemia (hemoglobin [Hb] <10 gr/dL).
- •Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
- •Chronic dialysis or known chronic renal failure (glomerular filtration rate (GFR)<30 ml/min/1.73m2).
- •Known moderate or severe hepatic impairment.
- •Severe uncontrolled chronic obstructive pulmonary disease.
- •Concomitant use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole, grapefruit juice over 1 litre daily), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine).
- •Concomitant use of drugs that are metabolized through cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) (omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol).
- •Increased risk of bradycardic events (e.g. known sick sinus syndrome or third degree atrioventricular (AV) block or previous documented syncope suspected to be due to bradycardia unless treated with a pacemaker).
- •Any known contraindication to clopidogrel, Acetylsalicylic Acid (ASA), or ticagrelor.
- •Current pregnancy, active lactation or parturition (childbirth) within the previous 30 days; women of childbearing potential must have a negative urine pregnancy test, or use a medically accepted method of birth control.
- •Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the completion of study participation.
- •Any non-cardiac condition with life expectancy less than 1 year.
- •Inability to adhere to the follow-up requirements or any other reason or condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.
研究组 & 干预措施
Ticagrelor
Active Comparator
1st day 270 mg & from then onwards 180 mg per day
干预措施: Ticagrelor (Drug)
Ticagrelor
Active Comparator
1st day 270 mg & from then onwards 180 mg per day
干预措施: Percutaneous Coronary Intervention (PCI) (Procedure)
Ticagrelor
Active Comparator
1st day 270 mg & from then onwards 180 mg per day
干预措施: Coronary Angiography (Procedure)
Clopidogrel
Active Comparator
1st day 300 mg & from then onwards 75 mg per day
干预措施: Clopidogrel (Drug)
Clopidogrel
Active Comparator
1st day 300 mg & from then onwards 75 mg per day
干预措施: Percutaneous Coronary Intervention (PCI) (Procedure)
Clopidogrel
Active Comparator
1st day 300 mg & from then onwards 75 mg per day
干预措施: Coronary Angiography (Procedure)
结局指标
主要结局
The difference in Post PCI Corrected TIMI Frame Count (CTFC) between the ticagrelor and clopidogrel treatment arms.
时间窗: 15 months after the initiation of the study.
次要结局
- The rates of TIMI Myocardial Perfusion Grade (TMPG) and the difference in the incidence of normal TMPG (3) following PCI between the ticagrelor and clopidogrel treatment arms.(15 months after the initiation of the study.)
- The rates of Pre and Post PCI TIMI Flow Grade (TFG) and the difference in the incidence normal epicardial flow (TFG 3) following PCI between the ticagrelor and clopidogrel treatment arms.(15 months after the initiation of the study.)
- The rates of full, partial and failed perfusion as assessed by the Angiographic Perfusion Score (APS) and the between treatment difference.(15 months after the initiation of the study.)
- The rates of Thrombolysis In Myocardial Infarction (TIMI) thrombus grades Pre and Post PCI and the difference in the incidence of thrombus grade '0' following PCI between the ticagrelor and clopidogrel treatment arms.(15 months after the initiation of the study.)
- The mean Global Longitudinal Strain (GLS) and Regional Longitudinal Strain (RLS) within 48 hours and at 30 and 90 days following PCI in the ticagrelor and clopidogrel treatment arms, and the between treatment difference.(15 months after the initiation of the study.)
- The mean Left Ventricular Ejection Fraction (LVEF) within 48 hours and at 30 and 90 days following PCI in the ticagrelor and clopidogrel treatment arms, and the between treatment difference.(15 months after the initiation of the study.)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Functional Coronary Angiography Guided Revascularization in STEMIMyocardial InfarctionNCT05818475University Hospital of Ferrara1,823
尚未招募
不适用
A Clinical Trial Evaluating the Pan-vascular Interventional Robotic System for Panvascularization Interventional SurgeryPercutaneous Coronary InterventionNCT06502938Shenzhen Institute of Advanced Biomedical Robot Co., Ltd.159
Unknown
4 期
Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic CardiomyopathyMyocardial DiseaseSystolic Heart FailureCardiomyopathyNCT00348530Medical University of Silesia120
已完成
4 期
Beyond 12 Hours Reperfusion AlternatiVe Evaluation TrialMyocardial InfarctionNCT00759629Deutsches Herzzentrum Muenchen365
招募中
4 期
Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane OxygenatorMulti Vessel Coronary Artery DiseaseExtracorporeal Membrane OxygenationAcute Myocardial InfarctionCardiogenic ShockNCT05527717Samsung Medical Center560